OmniAb, Inc. (OABI)

Over the past six months, OmniAb's stock price has been impacted by several events. The company reported strong first-quarter 2026 financial results, with revenue surging 247% year-over-year, and raised its full-year 2026 revenue guidance. The Q1 2026 financial results included a non-cash write-off of $2.9 million related to certain legacy small molecule ion channel intangible assets. Insiders made bullish purchases, acquiring US$1.28 million worth of stock. The CFO sold 6,913 shares of company stock. The company reported its fourth-quarter and full-year 2025 financial results and participated in the Leerink Partners Global Healthcare Conference. A 10% pullback in OmniAb's stock price contributed to year-long losses. The launch of OmniUltra was highlighted. The company reported its third-quarter 2025 financial results and participated in three investor conferences.

There is no direct indication of demand seasonality for OmniAb, Inc.'s products and services. The company's revenue is primarily driven by license fees, research support payments, milestone payments, and royalties, which are dependent on the progress of partner programs through clinical development rather than seasonal consumer demand. Artificial intelligence (AI) is seen as a "tailwind" for the industry, potentially accelerating demand for their data-generating platform.

OmniAb, Inc. is a technology company in the professional, scientific, and technical services sector, focusing on biotechnology and medical research. It licenses discovery research platforms to facilitate the discovery of next-generation therapeutics, using a business model centered on providing proprietary technology in exchange for milestone payments and royalties. The company's core offering is its "Biological Intelligence™" (BI) platform, which leverages proprietary, engineered transgenic animals to generate optimized antibody candidates for human therapeutics. Major products and platforms include transgenic animals like OmniRat®, OmniMouse®, and OmniChicken®; bispecific antibody platforms like OmniFlic® and OmniClic®; unique antibody characteristics from OmniTaur™ and OmnidAb™; peptide discovery through OmniUltra™; and screening and optimization tools like xPloration® and OmniDeep™. These technologies support drug discovery efforts for various conditions, including metabolic disorders, oncology, seizure disorders, and autoimmune diseases.

OmniAb, Inc. is headquartered in Emeryville, California, with an Ion Channel Technology Center in Durham, North Carolina. The company's partner base is geographically diversified, with 55% of partners based in the United States, 23% in Europe, 21% in Asia, and 1% in the Middle East.

OmniAb is recognized as a leader in therapeutic antibody discovery, providing cutting-edge discovery research technology to the pharmaceutical and biotech industries. The company emphasizes its "Biological Intelligence™" platform and its comprehensive suite of clinically proven antibody discovery technologies. OmniAb has a growing partner base, which included 107 active partners as of March 31, 2026, with eight of the world's ten largest pharmaceutical companies among them. There haven't been specific events reported that negatively impacted OmniAb's brand reputation, beyond general stock market fluctuations. Analysts currently have a consensus "Hold" rating for OmniAb, with a significant upside potential.

OmniAb, Inc. has a diverse ownership structure. Institutional investors hold a significant portion, ranging from 26.90% to 58.34% of the company's shares. Insiders own approximately 15.29%, while retail investors hold between 31% and 57.81%. Major institutional owners include Whitefort Capital Management, LP, BlackRock, Inc., Vanguard Group Inc, and others. Avista Capital Holdings, L.P. was noted as the largest shareholder with 11% ownership as of January 2026. Robert Goldstein is also listed as a significant individual shareholder.